5-HTP for Mood: How the Serotonin Precursor Works

5-HTP for Mood: How the Serotonin Precursor Works

▶ Watch the video

By Jack Zheng, MS Pharmacy — Founder of MIHIYO Labs

Summary

5-HTP (5-hydroxytryptophan) is the compound the body converts directly into serotonin, and limited controlled evidence suggests a possible benefit for depressed mood, although the clinical evidence remains small, dated, and heterogeneous in dose and study design. Oral 5-HTP can undergo peripheral decarboxylation before reaching the central nervous system: an enzyme called aromatic amino acid decarboxylase converts 5-HTP into serotonin outside the brain, which is why studies pairing 5-HTP with a decarboxylase inhibitor like carbidopa report markedly higher plasma levels than 5-HTP alone. MIHIYO Labs formulates its Mood-Boost oral dissolving strip (ODS) with that peripheral-conversion mechanism in mind and states plainly where the human evidence for 5-HTP stops.

Does 5-HTP actually raise serotonin, and does that help mood?

5-HTP is the immediate metabolic precursor of serotonin — the body takes the amino acid tryptophan, converts it to 5-HTP, then converts 5-HTP to serotonin in a single enzymatic step. Supplementing with 5-HTP skips the first, rate-limiting conversion, which is the reason it is sold as a more direct route to raising serotonin than tryptophan itself.1 The evidence on whether that translates into better mood is real but thinner than the marketing around it suggests: a Cochrane systematic review screened 108 studies but found only two trials, covering 64 people, that met its inclusion criteria; those trials, which pooled 5-HTP with tryptophan, trended toward benefit over placebo on depression scales, but the reviewers concluded the evidence was too limited in quality and quantity to recommend either substance for routine clinical use.2 That is the honest starting point for this article — a genuine mechanism, a preliminary and far from settled trial record. Doses varied widely across the literature; many of the older depression trials reviewed by Turner and colleagues used approximately 200 to 300 mg per day, some split the daily dose into smaller doses, in part because gastrointestinal adverse effects such as nausea appear to be dose-related and may be reduced with smaller individual doses.1

How does 5-HTP become serotonin, and why doesn't all of it reach the brain?

The enzyme that converts 5-HTP to serotonin is aromatic amino acid decarboxylase (AADC), and it is not confined to the brain — it is abundant in the gut wall, liver, and other peripheral tissue.3 Oral 5-HTP can undergo this peripheral decarboxylation before reaching the central nervous system, and the serotonin produced that way does not cross the blood-brain barrier — it stays outside the central nervous system and can instead drive gut and cardiovascular effects, including nausea. This peripheral conversion is the mechanistic reason researchers have paired oral 5-HTP with decarboxylase-inhibiting drugs in some studies; it is not a claim about a precise fraction lost when 5-HTP is taken alone, which has not been directly quantified in humans.

Human pharmacokinetic data provide some information on 5-HTP absorption and elimination, although the available studies are small. In a small steady-state dosing study of five patients with myoclonic disorders, all also taking a peripheral decarboxylase inhibitor, oral 5-HTP reached peak plasma concentration at roughly 1.8 to 3.3 hours, and the area under the plasma concentration curve rose in rough proportion to the dose, consistent with linear pharmacokinetics.4 A separate pharmacokinetic study in healthy subjects, also using carbidopa pretreatment, reported a biological half-life for 5-HTP of roughly 2.2 to 7.4 hours.9 Because peripheral decarboxylation limits how much 5-HTP survives intact, researchers have paired oral 5-HTP with carbidopa, a peripheral decarboxylase inhibitor that cannot cross the blood-brain barrier itself; co-administration has been shown to markedly increase plasma 5-HTP levels.1 That combination is a research tool, not an over-the-counter product — carbidopa is a prescription drug, and MIHIYO does not combine it with 5-HTP in any product.

How an oral 5-HTP dose splits between peripheral tissue and the central nervous system The same enzyme, aromatic amino acid decarboxylase, converts 5-HTP to serotonin both in peripheral tissue like the gut and liver and in the brain, but only serotonin made after 5-HTP reaches the central nervous system intact is associated with central mood effects; serotonin made peripherally cannot cross the blood-brain barrier. Oral 5-HTP dose Gut and liver (periphery) Central nervous system AADC converts to serotonin Same enzyme, peripheral tissue AADC converts to serotonin Same enzyme, brain tissue Stays outside the CNS Gut and cardiovascular effects Available centrally Associated with mood effects In research settings, carbidopa (a prescription decarboxylase inhibitor) can block the peripheral step above.

What do the depression and anxiety trials actually show?

The clinical record on 5-HTP is older than most supplement literature and smaller than it should be for a compound this widely sold. Byerley and colleagues' 1987 review of the antidepressant trials available at the time concluded 5-HTP showed antidepressant activity with relatively few adverse effects, but called for larger, better-controlled studies — a call the field only partly answered in the decades since.5 A recent small randomized study in generally healthy older adults provides additional, preliminary mood data, though it was not a trial in diagnosed depression: 30 adults in Singapore, mean age in the mid-to-late 60s, took either 100 mg of 5-HTP or a no-supplement control nightly for 12 weeks. The 5-HTP group's Geriatric Depression Scale score improved significantly from a low baseline by week 8, and a cognitive screening score improved modestly, but there was no significant change on a separate anxiety measure.6

That last point matters, because anxiety and depression are often marketed together under "mood support" but the 5-HTP evidence does not support them equally. In one of the few controlled anxiety trials, patients with DSM-III anxiety disorders were randomized to 5-HTP, the antidepressant clomipramine, or placebo; 5-HTP produced a moderate reduction in general symptom and anxiety scores compared with placebo, clearly less than clomipramine achieved, and it did not improve the depressive symptoms that often accompany anxiety the way clomipramine did.7

Study Population Intervention / Dose Duration Result
Shaw, Turner, Del Mar (Cochrane, 2002) 2 pooled RCTs meeting inclusion criteria (64 people total), unipolar depression Varied across pooled trials Varied Trended better than placebo on depression scales; evidence judged too limited in quality/quantity for routine use2
Byerley et al. (1987) Review of depression trials available at the time Varied across pooled trials Varied Antidepressant activity reported; authors called for larger trials5
Li et al. (2025) 30 generally healthy older adults, mean age 66–67 (not a depression-diagnosed sample) 100 mg/night 12 weeks 5-HTP vs. no-supplement control (not placebo-blinded); significant within-group GDS improvement from a low baseline by week 8; no significant anxiety change6
Kahn et al. (1987) 45 adults, DSM-III anxiety disorder 5-HTP vs. clomipramine vs. placebo; dose not stated in abstract Several weeks Moderate anxiety-score reduction vs. placebo, less than clomipramine; no benefit for co-occurring depressive symptoms7
Illustrative shape of 5-HTP plasma concentration over time, based on published Tmax and half-life ranges Schematic curve, not measured concentration data: published human studies using carbidopa pretreatment reported 5-HTP reaching peak plasma concentration around 1.8 to 3.3 hours after an oral dose, with a biological half-life of roughly 2.2 to 7.4 hours. Plasma 5-HTP (illustrative) Hours after dose 0 2 4 6 8 Tmax 1.8–3.3 h Half-life ≈ 2.2–7.4 h Healthy subjects, carbidopa pretreatment Curve shape is illustrative only; both source studies used carbidopa pretreatment, not 5-HTP taken alone, so absolute plasma levels are not shown.

What this means for the Mood-Boost ODS

I hold every MIHIYO formulation to the same two metrics: bioavailability and time to peak plasma concentration. Neither has been measured for the Mood-Boost strip itself — no MIHIYO product has published human pharmacokinetic data — so what follows is a design rationale, not a clinical claim. A film that dissolves and is swallowed very quickly may leave limited opportunity for transmucosal absorption, which is why maintaining mucosal contact during dissolution is part of the formulation strategy. That is a formulation-design principle I apply to every strip regardless of active ingredient, not a measured absorption outcome for any specific molecule.

Given that peripheral AADC activity is a well-established bottleneck for orally swallowed 5-HTP, a delivery route designed to permit the possibility of some transmucosal absorption — potentially bypassing part of first-pass gut and liver metabolism — is a mechanistically motivated design choice.3 Whether meaningful transmucosal absorption of 5-HTP actually occurs with this formulation has not been established in human pharmacokinetic studies, and I won't claim otherwise. It is not the same claim as "this strip delivers more serotonin to the brain" — nobody has run that trial on this product. The Mood-Boost ODS pairs 5-HTP with L-theanine; I've written separately about why that pairing shows up together and about why time-to-peak-concentration is a metric labels routinely leave out.

Where the evidence for 5-HTP falls short

Four limits deserve equal weight to the mechanism above. First, the trial base is small, old, and heterogeneous in dose and duration — several of the foundational depression trials predate modern reporting standards, and the Cochrane reviewers said so directly rather than papering over it.2 A handful of positive small trials is not the same evidentiary standard as an FDA-approved antidepressant, and I'm not implying it is.

Second, 5-HTP raises serotonin, and combining anything that raises serotonin with a serotonergic antidepressant — an SSRI, SNRI, or MAOI — creates a plausible and potentially serious risk of serotonin toxicity (serotonin syndrome), a combination of altered mental status, autonomic instability, and neuromuscular symptoms. A published case report describes a patient on sertraline who developed serotonin syndrome with rhabdomyolysis progressing to acute compartment syndrome after taking several dietary supplements, including 5-HTP, alongside his prescribed antidepressant; the report does not isolate 5-HTP as the sole cause among the supplements involved, but it supports the clinical plausibility of a serotonergic supplement–drug interaction.10 Anyone on a serotonergic medication should not add 5-HTP without their prescriber's involvement.

Third, peripheral conversion of 5-HTP to serotonin can also contribute to gastrointestinal adverse effects such as nausea and vomiting, since serotonin acts on receptors in the gut wall as well as the central nervous system.13 This is a mechanistically plausible side effect rather than a rare idiosyncratic reaction. This is one reason gradual dose escalation has been used in some clinical protocols.

Fourth, sourcing has a documented history worth knowing. In the late 1990s, Klarskov and colleagues identified contaminant peaks — the so-called "Peak X" family — in all eight commercial 5-HTP samples they tested, structurally reminiscent of the contamination linked to the 1989 L-tryptophan eosinophilia-myalgia syndrome outbreak, though 5-HTP itself has not been tied to a confirmed outbreak of that scale.8 That history is a sourcing and quality-control argument, not a reason to avoid the molecule outright, but it is a reason I hold raw-material testing to a higher bar than "it's a common supplement ingredient" would suggest on its own.

The bottom line

5-HTP for mood has a real, well-described mechanism — direct conversion to serotonin — and limited, dated, but directionally positive trial evidence for depressed mood specifically; the case for anxiety is weaker and less consistent.2567 Orally swallowed 5-HTP is subject to peripheral decarboxylation before reaching the central nervous system.34 I built the Mood-Boost ODS around that mechanism, not around a promise the evidence doesn't yet support — and anyone taking a serotonergic medication should treat 5-HTP as a drug-interaction question, not a supplement aisle decision.

References

  1. Turner EH, Loftis JM, Blackwell AD. Serotonin a la carte: supplementation with the serotonin precursor 5-hydroxytryptophan. Pharmacology & Therapeutics. 2006;109(3):325–338. PMID: 16023217. DOI: 10.1016/j.pharmthera.2005.06.004. https://pubmed.ncbi.nlm.nih.gov/16023217/
  2. Shaw K, Turner J, Del Mar C. Tryptophan and 5-hydroxytryptophan for depression. Cochrane Database of Systematic Reviews. 2002;(1):CD003198. PMID: 11869656. DOI: 10.1002/14651858.CD003198. https://pubmed.ncbi.nlm.nih.gov/11869656/
  3. Nakamura K, Hasegawa H. Production and peripheral roles of 5-HTP, a precursor of serotonin. International Journal of Tryptophan Research. 2009;2:37–43. PMID: 22084581. DOI: 10.4137/ijtr.s1022. https://pmc.ncbi.nlm.nih.gov/articles/PMC3195225/
  4. Magnussen I, Nielsen-Kudsk F. Bioavailability and related pharmacokinetics in man of orally administered L-5-hydroxytryptophan in steady state. Acta Pharmacologica et Toxicologica (Copenh). 1980;46(4):257–262. PMID: 6966118. DOI: 10.1111/j.1600-0773.1980.tb02451.x. https://pubmed.ncbi.nlm.nih.gov/6966118/
  5. Byerley WF, Judd LL, Reimherr FW, Grosser BI. 5-Hydroxytryptophan: a review of its antidepressant efficacy and adverse effects. Journal of Clinical Psychopharmacology. 1987;7(3):127–137. PMID: 3298325. https://pubmed.ncbi.nlm.nih.gov/3298325/
  6. Li S, Sutanto CN, Xia X, Kim JE. The impact of 5-hydroxytryptophan supplementation on cognitive function and mood in Singapore older adults: a randomized controlled trial. Nutrients. 2025;17(17):2773. PMID: 40944161. DOI: 10.3390/nu17172773. https://pmc.ncbi.nlm.nih.gov/articles/PMC12430700/
  7. Kahn RS, Westenberg HGM, Verhoeven WMA, Gispen-de Wied CC, Kamerbeek WD. Effect of a serotonin precursor and uptake inhibitor in anxiety disorders; a double-blind comparison of 5-hydroxytryptophan, clomipramine and placebo. International Clinical Psychopharmacology. 1987;2(1):33–45. PMID: 3312397. DOI: 10.1097/00004850-198701000-00003. https://pubmed.ncbi.nlm.nih.gov/3312397/
  8. Klarskov K, Johnson KL, Benson LM, Gleich GJ, Naylor S. Eosinophilia-myalgia syndrome case-associated contaminants in commercially available 5-hydroxytryptophan. Advances in Experimental Medicine and Biology. 1999;467:461–468. PMID: 10721089. DOI: 10.1007/978-1-4615-4709-9_58. https://pubmed.ncbi.nlm.nih.gov/10721089/
  9. Westenberg HGM, Gerritsen TW, Meijer BA, van Praag HM. Kinetics of l-5-hydroxytryptophan in healthy subjects. Psychiatry Research. 1982;7(3):373–385. PMID: 6187038. DOI: 10.1016/0165-1781(82)90074-9. https://pubmed.ncbi.nlm.nih.gov/6187038/
  10. Patel YA, Marzella N. Dietary supplement-drug interaction-induced serotonin syndrome progressing to acute compartment syndrome. American Journal of Case Reports. 2017;18:926–930. PMID: 28839121. DOI: 10.12659/AJCR.904375. https://pubmed.ncbi.nlm.nih.gov/28839121/

By — Founder of MIHIYO Labs. Focused on the R&D of high-bioavailability, fast-absorption oral dissolving strips.

0 comments

Leave a comment

Please note, comments need to be approved before they are published.